Hanmi Pharm's impotence drug "Gugu" will enter the Japanese market with "BPH," which has secured first generic status. Sandoz, one of Japan's leading pharmaceutical companies, will take charge of sales in the Japanese market.
Hanmi Pharm announced on Feb. 26 that it has obtained a market license for two types of Gugu, 2.5 mg (Ingredient: Tadalafil) and 5 mg, from Japanese licensing authorities.
They will be released on the Japanese market through Sandoz starting in June. The Japanese product is called "Sandoz Tadalafil (2.5/5 mg).
Hanmi Pharm produces Gugu finished products and supplies them to Sandoz, which packages them and then takes charge of sales and marketing across Japan. The export marks the first time that an oral finished drug developed by Hanmi Pharm has entered Japan.
The overall market for Tadalafil BPH in Japan is 63 million units per year (IMS-based 2018). Hanmi Pharm plans to continue close cooperation with Sandoz with the aim of securing the largest share of Japan's BPH market in the future.
"It is meaningful that the Gugu, which is making solid progress in the Korean urinary system market, will explore a new market in Japan with first generic," an official of Hanmi Pharm said. "We will work hard to achieve meaningful results in Japan's BPH market through solid cooperation with our partner."
